Emcure Pharma IPO lists @ Rs. 1325

July 10, 2024 admin Leave a reply Post Comment

Emcure Pharmaceuticals IPO GMP date review price allotment details @ Chanakyanipothi.com,

👉A legacy of 31 Years.
India`s Oldest Investment & IPO website.
👉Most Trusted by Investors across India.

Table of Contents

• GMP
• Reviews
• Subscription
• Allotment

What is the business of Emcure Pharmaceuticals?

Emcure Pharmaceuticals is one of the leading Indian pharmaceutical companies engaged in developing, manufacturing and globally marketing a broad range of pharmaceutical products across several major therapeutic areas. It is a R&D driven company with a differentiated product portfolio that includes orals, injectables and biotherapeutics, which has enabled it to reach a range of target markets across over 70 countries, with a strong presence in India, Europe and Canada. It was ranked as (i) the 13th largest pharmaceutical company in India in terms of Domestic Sales for MAT September 2023, (ii) the 4th largest pharmaceutical company by market share in its Covered Markets in terms of Domestic Sales for MAT September 2023, and (iii) the largest pharmaceutical company in the gynecology and human immunodeficiency virus (“HIV”) antivirals therapeutic areas in India in terms of Domestic Sales for MAT September 2023.

Its sales in India contributed to 50.84% and 53.16% of its total revenue from operations for the six months ended September 30, 2023 and the Financial Year 2023, respectively. Between MAT September 2019 and MAT September 2023, its Domestic Sales grew at a CAGR of 10.80%, outperforming the Indian pharmaceutical market (“IPM”), which grew at a CAGR of 8.23%, by 1.3 times. It had a Covered Market presence of 52.14% of the IPM in terms of Domestic Sales for MAT September 2023.
Across all such therapeutic areas, it ranked among the 10 largest pharmaceutical companies in India in terms of Domestic Sales for MAT September 2023. Sales of its iron, chiral, biotherapeutics, injectables and photo-chemistry products contributed to 54.43% and 51.40% of its revenue from sales in India for the six months ended September 30, 2023 and the Financial Year 2023, respectively, demonstrating its approach towards establishing a differentiated product portfolio.

Brand Ranking & portfolio

Emcure has demonstrated strong capabilities and a proven track record in building brands. Eight of its brands were ranked among the 300 highest selling brands in the IPM, in terms of Domestic Sales for MAT September 2023. It had 28 brands with Domestic Sales of over Rs 500.00 million for MAT September 2023, as compared to 13 brands for MAT September 2019. In addition, 17 of its top 20 brands were each ranked among the three highest selling brands in their respective therapeutic areas in the IPM, in terms of Domestic Sales for MAT September 2023.

The company also sells its portfolio of differentiated products internationally in over 70 countries.
It is an R&D driven company and its core strength lies in our ability to research, develop and manufacture inhouse specialty pharmaceutical products for high-growth therapeutic areas, for which there is limited competition and high barriers to entry. As of September 30, 2023, it had a team of 552 qualified scientists and five dedicated R&D facilities in India. As of September 30, 2023, it had filed over 1,800 dossiers globally including 204 in the European Union and 133 in Canada. In addition, as of September 30, 2023, it had been granted 201 patents and had 33 pending patent applications in several countries, and had submitted 102 drug master files for APIs with the U.S. Food and Drug Administration (“USFDA”)
Emcure has 13 manufacturing facilities across India.

For more information, click www.emcure.com

Emcure Pharmaceuticals IPO Review

Emcure Pharmaceuticals is one of the leading Indian pharmaceutical companies engaged in developing, manufacturing and globally marketing a broad range of pharmaceutical products across several major therapeutic areas. It is a R&D driven company with a differentiated product portfolio that includes orals, injectables and biotherapeutics, which has enabled it to reach a range of target markets across over 70 countries, with a strong presence in India, Europe and Canada. 
Size: The size of the IPO is Rs. 1952.03 crore and considering the market euphoria, the size is not very large. The HNI portion is Rs. 292.80 crore and retail portion is Rs. 683.21 crore. The IPO is expected to receive huge over subscription.
Financials: The company has shown rangebound trend in its topline and bottomline during last 3 years. According to the explantion provided by the management, the company has incurred huge promotional/ sales and marketing expenses during  last year and the fruits of the same will be availed in the year 2024-25. In spite of low profits, the shares are offered at PE Multiple of 36.60 and compared to other leading pharma companies, the shares are offered at not so high valuation. Looking to its leadership position in some of the product categories and very sound balancesheet, one must apply and it offers good for strong listing gains. Because of the Shark Tank presence and goodwill of one of the promoters, huge over subscription is possible.
+ from Fundamental Angle= Apply
+ from Grey Market Angle= Apply

Quicklinks

• Staffavailable
• BigGaddi
• ChanakyaMF
• Magajmari

Emcure Pharmaceuticals IPO GMP

Emcure Pharmaceuticals IPO GMP today review details

Emcure Pharmaceuticals IPO GMP today, Details, review, Subscription Status, allotment